TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
92.00
+27.90 (43.53%)
At close: Mar 6, 2026
324.94%
Market Cap 36.71B
Revenue (ttm) n/a
Net Income (ttm) -259.80M
Shares Out 399.00M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31,144,970
Average Volume 2,780,072
Open 64.45
Previous Close 64.10
Day's Range 63.00 - 93.30
52-Week Range 20.20 - 679.50
Beta n/a
RSI 63.06
Earnings Date Jun 9, 2026

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 121
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2617
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.